Polyvalent inactivity vaccine for preventing and treating atrophic rhinitis of swine

A technology for atrophic rhinitis and inactivated vaccines, applied in the direction of antibody medical components, medical preparations containing active ingredients, bacterial antigen components, etc., can solve problems such as incomplete absorption, less protective antigen components, and restrictions on the application of PMT. Achieve effective treatment and prevention, high immune protection efficacy, and low production cost

Active Publication Date: 2013-07-03
PU LIKE BIO ENG
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the steps for producing PMT toxoid are complicated. In the prior art, the toxin-producing strain Pm of Pasteurella multocida is cultivated for up to 26 hours with blood medium at 37°C, or the brain-heart extract meat After culturing the brain heart infusionbroth (BHI broth) for 72 hours, extract and concentrate PMT, and inactivate the harvested toxin with 1% formalin at 37°C for 4 days to obtain low toxicity but still antigenic toxoid
Therefore, in addition to the cumbersome preparation methods, the cost of preparing PMT inactivated into vaccine antigens is very high, which also limits the application of PMT in swine atrophic rhinitis.
[0006] At present, the porcine atrophic rhinitis vaccine used in my country is mainly Bordetella bronchiseptica (Bb) inactivated vaccine or Bordetella bronchiseptica (Bb) plus toxin-producing Pasteurella multocida type D (Pm- D) Inactivated vaccines, the adjuvants used are usually aluminum gel adjuvant, Freund's adjuvant, and water-in-oil adjuvant, which have few protective antigen components, cannot provide complete protection, and are not fully absorbed after injection. , side effects and other disadvantages

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polyvalent inactivity vaccine for preventing and treating atrophic rhinitis of swine
  • Polyvalent inactivity vaccine for preventing and treating atrophic rhinitis of swine
  • Polyvalent inactivity vaccine for preventing and treating atrophic rhinitis of swine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The preparation of the polyvalent inactivated vaccine of embodiment 1 porcine atrophic rhinitis

[0032] 1. The source and identification of the bacterial classification of the embodiment of the present invention

[0033] 1.1 The source of strains

[0034] The preservation number of Bordetella bronchiseptica (Bb) HN8 strain is CCTCC NO: M2011223, the preservation number of Pasteurella multocida (Pasteurella multocida) type A HN5 strain is CCTCC NO: M2011222, Pasteurella multocida The deposit number of the D-type HB4 strain is CCTCC NO: M2011221. The strains of the above three strains were isolated and identified by Pulaike Bioengineering Co., Ltd. The vaccine prepared by the above strains has good immunity and strong specificity, and has an irreplaceable role for other strains.

[0035] 1.2 Identification of strains

[0036] 1.2.1 Biochemical identification

[0037] Bronchiseptica Bordetella HN8 strain had hemolysis; catalase, oxidase, urease, citrate, sodium chloride...

Embodiment 2

[0064] The preparation of the polyvalent inactivated vaccine of embodiment 2 porcine atrophic rhinitis 2

[0065] The inactivation of bacterial classification and bacterial classification, the extraction of PMT toxoid and inactivation are the same as embodiment 1.

[0066] See Table 1 below for the ratio of each antigen in Example 2.

Embodiment 3

[0067] The preparation of the polyvalent inactivated vaccine of embodiment 3 porcine atrophic rhinitis 3

[0068] The inactivation of bacterial classification and bacterial classification, the extraction of PMT toxoid and inactivation are the same as embodiment 1.

[0069] See Table 1 below for the ratio of each antigen in Example 3.

[0070] The concrete proportioning ratio of the vaccine of embodiment 1-3 is shown in Table 1:

[0071] The composition ratio of the polyvalent inactivated vaccine of table 1 porcine atrophic rhinitis

[0072]

[0073]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a polyvalent inactivity vaccine for preventing and treating atrophic rhinitis of a swine and a preparation method thereof. The polyvalent inactivity vaccine contains inactivated Bordetella bronchiseptica, Pasteurella multocida A, Pasteurella multocida D and PMT (Pasteurella Multocida Toxin) anatoxin. The invention further provides a novel method for culturing and extractingPMT. Compared with the traditional atrophic rhinitis of the swine, the polyvalent inactivity vaccine for the atrophic rhinitis of the swine, provided by the invention, can be used for more generally and effectively treating and preventing the atrophic rhinitis of the swine by comprehensive antigen protection. Finally, in the polyvalent vaccine provided by the invention, the vaccine with a plurality of antigens in a reasonable proportion can be used for solving the problem that the plurality of the antigens interfere each other, thereby improving an immune effect. Furthermore, the inventor provides a water adjuvant by which defects such as incomplete absorption, large side reaction and the like after the traditional alumina gel adjuvant, Freund adjuvant and water-in-oil adjuvant are injected into the water adjuvant can be overcome.

Description

technical field [0001] The invention relates to a multivalent inactivated vaccine for preventing and treating porcine atrophic rhinitis, in particular to a water-based adjuvant inactivated vaccine for porcine atrophic rhinitis containing multiple antigens. Background technique [0002] Porcine atrophic rhinitis (atrophic rhinitis, AR) is an important respiratory infectious disease in pigs. It can cause symptoms such as chronic rhinitis, sneezing, tearing, facial degeneration and turbinate atrophy in pigs. It can cause snout deformation and affect the bone development of the whole body, thereby causing growth retardation of pigs, making pigs susceptible to secondary complex pneumonia, and causing huge losses to the pig industry. The disease can infect pigs of any age, among which the infection rate of pigs within 4 weeks of age is the highest, and symptoms generally appear at 8-12 weeks of age. [0003] Porcine atrophic rhinitis can be divided into progressive atrophic rhini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/116A61K39/102A61K39/10A61P31/04
Inventor 张许科孙进忠白朝勇
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap